Invivyd, Inc. IVVD
Updated: 9 Aug 2026
No signal published yet
We already track Invivyd and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Invivyd, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Invivyd free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 6, 2026, Invivyd announced receipt of a twelve-month advance notice from the U.S. FDA that Emergency Use Authorization for PEMGARDA will terminate in June 2027. Additionally, on July 23, 2026, the company received a deficiency notice from Nasdaq regarding its minimum bid price requirement. Invivyd is engaging with regulatory authorities while advancing its clinical pipeline programs.
What Firelda Watch includes for Invivyd, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Invivyd, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Invivyd free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more